Irazu Oncology is a preclinical stage biotech company, founded in 2022 and headquartered at the University of Maryland BioPark, in Baltimore. Irazú Oncology’s mission is to develop flexible and cost-effective cancer vaccines utilizing bacterial outer membrane vesicle (OMVs) technology to target solid tumors.